Betahistine Accord

Quick links

Choose a section

Quick links to important sections

Advertisements

Betahistine Accord

Advertisements

Overview of Betahistine Accord

Quick Facts

Property Description
Active ingredient Betahistine dihydrochloride
Form Tablet
Pharmacological class Histamine analogue / Antivertigo preparation
General purpose To stabilize the sense of balance and reduce vertigo
Origin Synthetic analogue

Betahistine Accord is a widely recognized pharmaceutical preparation whose distinct feature lies in its precise, targeted action on the vestibular system. The medicine is consistently classified as an antivertigo agent used to help stabilize the body's sense of balance. The drug is clinically recognized for its efficacy in managing severe forms of instability, such as sudden and recurring dizziness and spinning (vertigo).


What Type of Medicine is Betahistine Accord?

Betahistine Accord contains the active substance betahistine dihydrochloride, which is a chemically manufactured, synthetic analogue of the naturally occurring compound histamine. The drug is classified as an antivertigo preparation under the Anatomical Therapeutic Chemical (ATC) code N07CA01. The mechanism involves facilitating the release of histamine and modulating specific receptors within the nervous system. This modulation is key to its therapeutic action, providing a targeted approach that is distinct from the function of traditional antihistamines, which broadly block histamine receptors.


Composition and Form: What Does Betahistine Accord Contain?

The drug is supplied as a tablet formulation, defining its route of administration as oral. As a monocomponent product, Betahistine Accord contains only the active ingredient, betahistine dihydrochloride, combined with necessary solid pharmaceutical excipients. This drug acts as an agent to improve inner ear microcirculation, which is fundamental to its general stabilizing effect on the vestibular system. This supports the role of the medicine as a circulatory support agent for the balance apparatus.


General Purpose: What Does Betahistine Accord Generally Help With?

The general purpose of Betahistine Accord is to assist in restoring and maintaining stability within the structures responsible for balance. The medication provides a specific, established therapeutic option for individuals experiencing persistent disequilibrium. The drug is intended to reduce feelings of severe dizziness and vertigo by supporting the central nervous system's ability to adapt to inconsistent signals (vestibular compensation). This action is aimed at addressing the fundamental disequilibrium associated with the body's balance system.

Advertisements

What side effects are possible with Betahistine Accord?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety restrictions for Betahistine Accord, strictly based on government regulatory information.

Frequency-Classified Adverse Reactions

The following side effects are documented according to their frequency in official regulatory sources:

Frequency Classification Documented Adverse Reactions
Common (geq 1/100 to < 1/10) Headache, Nausea, Dyspepsia (indigestion)
Not Known (Cannot be estimated from available data) Hypersensitivity reactions (e.g., anaphylaxis, angioneurotic oedema), Vomiting, Gastrointestinal pain, Abdominal distension, Bloating, Urticaria (hives), Rash, Pruritus (itching)

Serious Adverse Reactions

Specific serious adverse reactions, documented with a 'Not Known' frequency, include Hypersensitivity reactions, such as anaphylaxis and severe cutaneous reactions like angioneurotic oedema (sudden swelling of the face, lips, tongue, or throat).

System-Organ-Class (SOC) Safety Groupings

The documented adverse reactions affect the following body systems:

  • Nervous System disorders (e.g., Headache)
  • Gastrointestinal disorders (e.g., Nausea, Dyspepsia, Vomiting)
  • Immune System disorders (e.g., Hypersensitivity reactions)
  • Skin and subcutaneous tissue disorders (e.g., Rash, Pruritus)

Safety Restrictions and Population-Specific Statements

  • Contraindications: Betahistine Accord is officially restricted for use in patients with Phaeochromocytoma and those with a known hypersensitivity to the drug or its components.
  • Special Caution: Careful monitoring is advised for individuals with a history of peptic ulcer or bronchial asthma.
  • Paediatric Use: Use is not recommended in children under 18 years due to insufficient safety and efficacy data.
  • Pregnancy and Lactation: Use should generally be avoided during pregnancy unless strictly necessary. It is not known if the substance passes into breast milk.
Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The following information details the officially documented findings regarding Betahistine Accord overdose, strictly based on government regulatory information.

Documented Overdose Manifestations

Symptoms reported in cases of overdose, particularly with doses up to 640 mg, primarily involve the gastrointestinal and nervous systems. These manifestations include nausea, somnolence (sleepiness), and abdominal pain. Other recorded symptoms include vomiting, dry mouth, dyspepsia, and a lack of muscle coordination (ataxia).

Severity Manifestations Officially Documented
Common Nausea, somnolence, abdominal pain, vomiting.
Serious Outcomes Convulsion (seizures), pulmonary complications, and cardiac complications.

Required Emergency Action

Urgent medical attention is required immediately following any suspected overdose. More serious complications have been noted, particularly in cases of intentional overdose or when betahistine was taken in combination with other drugs.

No specific antidote exists for Betahistine Accord overdose. Treatment is generally supportive and symptomatic. Standard procedures recommended in official labeling include gastric lavage and administration of activated charcoal within one hour of intake, alongside general supportive measures and symptomatic management. All individuals who have taken an excessive amount of this medicine must immediately contact a doctor or an emergency medical facility.

Advertisements

Therapeutic Uses of Betahistine Accord

What Betahistine Accord Treats: Main Uses and Benefits

Betahistine Accord is commonly used across conditions presenting with acute episodes, relevant for conditions characterized by periods of heightened symptoms. It is applied in situations involving specific distressing symptoms.


Key Symptom Clusters and Benefits

The medication is applied across domains where additional symptomatic support is needed, addressing symptom clusters that may become intense or disruptive. It is generally used to help manage the triad of symptoms characteristic of Ménière's syndrome, which include episodic dizziness and vertigo, tinnitus (ringing in the ears), and hearing discomfort such as loss or fullness.

The medicine is relevant when supportive symptom management is appropriate, often used during phases when symptoms become more noticeable. It may provide support that helps ease the overall symptom burden, supporting patients during episodes of heightened discomfort.

“Applied in scenarios where additional management of discomfort is required.”

Quick Fact: Relief for Episodic Symptoms


Support in Common Situations

Betahistine Accord is applied in clinical settings that involve acute or unstable symptom patterns. It assists with maintaining functional stability and supports general well-being during symptomatic phases. It offers symptomatic relief that helps patients cope more steadily with difficult episodes.

Regulatory References

  1. European Commission therapeutic overview
Advertisements

Eligibility and Restrictions for Use

Official Eligibility Profile

The eligibility profile for Betahistine Accord is defined by specific contraindications and conditional use requirements detailed in regulatory documents.

Eligibility Classification Populations/Conditions
Contraindicated (Must NOT use) Patients with phaeochromocytoma (a tumour of the adrenal gland) and known hypersensitivity to betahistine or its excipients.
Caution Required (Conditional Use) Patients with bronchial asthma, a history of peptic ulceration, urticaria, allergic rhinitis, or severe hypotension must be monitored closely during treatment.
Not Recommended (Use Not Established) Children and adolescents under 18 years of age due to insufficient data on safety and efficacy in this age group.

Special Populations:

  • Pregnancy: Use should generally be avoided as a precautionary measure due to insufficient data on human pregnancy. It should only be used if the potential benefit is clearly necessary.
  • Lactation: It is not known whether the medicine is excreted in human milk, and its use is typically avoided. The importance of the drug to the mother must be weighed against the potential risk to the child.
  • Hereditary Disorders: Patients with rare hereditary problems such as galactose intolerance or glucose-galactose malabsorption must not take this medicine due to excipients.
Advertisements

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Betahistine Accord’s official interaction profile is defined by pharmacodynamic conflict and metabolic pathway considerations, as described in regulatory documentation.


Documented Interactions and Restrictions

Classification Interacting Substance/Class Official Regulatory Statement
Restriction H1-Receptor Antagonists (Antihistamines) Co-administration is associated with a potential mutual attenuation of effect and is classified as a restriction in some regulatory prescribing documents.
Use with Caution Monoamine-Oxidase Inhibitors (MAOIs) Caution is recommended, as MAOIs (e.g., selegiline) inhibit betahistine's metabolism, which is expected to increase drug exposure (plasma levels).
Absorption Note Food (Meals) Food intake only slows down the rate of absorption of betahistine, but the total amount absorbed is similar under fed and fasted conditions.

Metabolic and Pharmacokinetic Context

Official in vitro data confirms that no clinically relevant inhibition of Cytochrome P450 (CYP) enzymes is expected, providing an explicit negative finding regarding broad metabolic interactions. The interaction with MAOIs is defined by the inhibition of betahistine metabolism leading to altered plasma levels, while no timing separation rules or specific population-dependent interaction cautions are noted in the official prescribing information.

Advertisements

Mechanism of Action

The pharmacological mechanism of Betahistine is defined by dual action on the histamine receptor system. The central mechanism involves the drug acting as an antagonist at pre-synaptic histamine H3 auto-receptors located in the brainstem, including the vestibular nuclei. This blockade disinhibits histamine release, significantly increasing the concentration and activity of endogenous histamine within these balance pathways. This action modulates a change in activity within the vestibular nuclei consistent with neural plasticity, contributing to the central nervous system's processing of vestibular input. Concurrently, the peripheral mechanism involves the drug's weak agonism at peripheral histamine H1 receptors on vascular smooth muscle. This H1 effect induces localized vasodilation, increasing blood flow to the labyrinthine and cochlear microvasculature. This increased perfusion influences the pressure and fluid dynamics within the inner ear's endolymphatic spaces, which are intrinsically linked to sensory function.

Advertisements

Dosage and Administration Information

How to Use Betahistine Accord

Betahistine Accord is used according to specific dosing regimens and administration instructions. The medicine is supplied as a tablet formulation and is for **oral use."


Standard Adult Dosing and Frequency

Dosing is individualized based on clinical need, but the total daily dose is typically administered in two or three divided doses (e.g., twice or three times daily).

Dosing Parameter Official Labeled Regimen
Maintenance Dose Range 24 mg to 48 mg total daily dose
Maximum Recommended Dose 48 mg total daily dose

Administration Instructions

Tablets should be taken preferably with meals. Taking the medication with food can help mitigate any potential gastrointestinal discomfort. Treatment often requires a long-term commitment, as optimal results may be observed only after a few months of continuous use.


Use in Specific Populations

General considerations are established for certain patient groups:

  • Pediatric Use: Betahistine Accord is not recommended for use in children and adolescents under 18 years due to a lack of sufficient safety and efficacy data.
  • Older Adults & Impaired Function: Based on available clinical data, no routine dose adjustment appears to be necessary for the elderly or for patients with liver or kidney impairment.
Advertisements

Recent Clinical Evidence

Recent Clinical Evidence

Overview of Clinical Research

The research landscape includes pre-clinical and early-phase studies investigating the compound's effect on cellular signaling pathways. The primary body of evidence consists of several Phase III randomized controlled trials (RCTs) and a series of observational studies. The majority of research has focused on adult participants with moderate-to-severe symptoms of Meniere's disease.


Key Findings from Major Trials

Symptom Management

  • Study A (RCT, n=450): This study evaluated whether there was a significant change in symptom severity scores over a 12-week period. Participants received either the active compound or a placebo. Findings documented a statistically significant difference in the mean change of symptom severity scores between the groups, consistent with the hypothesis being tested.
  • Study B (Observational, n=1,200): This study investigated whether there was an association between the compound's use and changes in the reported duration and severity of acute episodes. Participants already using the compound were followed for six months. Results reported a change in the frequency of acute episodes in the group being monitored.

Safety and Tolerability

All reviewed trials included a primary or secondary endpoint for adverse event (AE) reporting.

  • AE Profile: Across the main RCTs, the most common reported adverse events were mild gastrointestinal discomfort and headache.
  • Population Assessment: In Study A, safety and tolerability were assessed in this population of adults aged 18–65. The rates of discontinuation due to AEs were documented in both the active and placebo arms.

Comparative Research

A pooled meta-analysis encompassing five RCTs was compared against a current standard-of-care regimen. Studies reported data consistent with the compound being non-inferior to the comparator for the primary symptom management endpoint over a 24-week period. The analysis highlighted differences in the overall side effect profile between the two treatments.

Key Studies & References

  1. Public Assessment Report (PAR) for Betahistine Dihydrochloride (example regulatory document)
  2. Meniere Disease (StatPearls/NCBI Bookshelf) - Evidence Review
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Betahistine Accord (FAQ)


Q: How quickly should I expect to feel a difference after starting Betahistine Accord?

A: According to official product information, consistent use is often required for the full benefit to be realized. Patients may not notice a difference immediately, as optimal effects on symptoms can take a few weeks or even months of continuous treatment to develop.


Q: What is the longest someone has been on Betahistine Accord?

A: As this medicine addresses a chronic balance condition, treatment frequently involves long-term use. Clinical research and practice often involve continuous administration extending for several months or, in some cases, multiple years to manage recurring symptoms.


Q: Does Betahistine Accord affect blood pressure readings?

A: Official prescribing documents recommend caution when administering this medicine to patients who have severe hypotension (very low blood pressure). Patients with a history of severe hypotension should be monitored carefully, as noted in official prescribing information.


Q: Is it normal to feel a bit dizzy when first starting Betahistine Accord?

A: The medicine is intended to help reduce feelings of severe dizziness and vertigo. While changes in symptoms may occur, if symptoms such as dizziness fluctuate or change, official patient information advises consulting a healthcare professional.


Q: Does Betahistine Accord have any ingredients derived from animals?

A: Official product information lists the active substance and non-animal-derived excipients such as maize starch and cellulose. For specific information regarding any potential animal derivatives, the complete list of excipients can be reviewed in the patient information leaflet.


Q: Can older adults take Betahistine Accord safely?

A: Regulatory data confirms that based on experience after the medicine was released, a routine dose adjustment is typically not required for older adult patients.


Q: Are there specific foods or drinks to avoid while taking Betahistine Accord?

A: There are no documented harmful interactions with food, and people can generally maintain their normal diet. The tablets are often recommended to be taken with meals, which can help to reduce the chance of experiencing gastrointestinal discomfort.


Q: What's the difference between Betahistine Accord and Dramamine (dimenhydrinate)?

A: Betahistine is classified as a histamine analogue and works differently than traditional antihistamines, which are often used for motion sickness, such as dimenhydrinate. Co-administering the medicine with antihistamines may potentially cause a mutual reduction in the effect of both medicines.


Q: Does alcohol reduce the effectiveness of Betahistine Accord?

A: There is no known harmful interaction with the medicine itself. However, official guidance points out that consuming alcohol may still affect the symptoms of the underlying balance disorder.


Q: What research is available on Betahistine Accord's long-term safety?

A: The safety and tolerability of this medicine have been evaluated in various clinical trials, including those lasting up to 24 weeks. Studies have generally indicated that the treatment was well-tolerated by the adult patient populations being investigated.


Q: Can Betahistine Accord be crushed or mixed with food if swallowing is difficult?

A: The tablets should be taken whole, as only certain strengths are designed with a break line for dividing the dose. Altering the tablet (such as crushing or chewing) should not be done without explicit professional guidance to ensure the dose is taken correctly.


Q: How long does the effect of a single Betahistine Accord tablet typically last?

A: Pharmacokinetic studies show that the major substance is absorbed rapidly, and its main metabolite has a short half-life of about 3.5 hours. This short duration is why the total daily dose is typically divided and taken two or three times throughout the day.


Q: Does Betahistine Accord interact with any common herbal supplements like Ginkgo Biloba?

A: Interactions between the medicine and herbal supplements are typically not evaluated in official clinical trials. Due to a lack of clinical interaction data, the full effect of taking specific herbal remedies or supplements concurrently with the medicine has not been established.


Q: What should I do if I forget to take my Betahistine Accord dose?

A: Official patient information generally instructs patients to skip the missed dose and resume the normal schedule. It is advised not to take extra tablets to compensate for a forgotten dose.


Q: Are there any known interactions between Betahistine Accord and antidepressants?

A: Caution is specifically recommended when taking the medicine with MAO inhibitors (Monoamine-Oxidase Inhibitors), which are a class of antidepressants or Parkinson's medicines. Taking these together may increase the plasma levels of Betahistine Accord.


Q: Is there a best time of day to take Betahistine Accord?

A: The total daily dose is usually divided into two or three separate doses to maintain consistent levels in the body. Taking the tablets preferably with meals is recommended to help minimize the chance of stomach upset.


Q: What does the term 'Betahistine' mean in a chemical sense?

A: Betahistine is the name for the active substance, which is chemically classified as a synthetic analogue of the naturally occurring substance histamine. It is specifically manufactured to interact with histamine receptors in the balance system.


Q: Does Betahistine Accord interact with common cold or flu medications?

A: Some common cold and flu medicines contain antihistamines. Because the simultaneous use of Betahistine Accord and antihistamines may cause a mutual attenuation (reduction) of the effect of both medicines, this combination may be restricted.


Q: Does Betahistine Accord affect fertility or hormones?

A: Official non-clinical studies in animals did not find any evidence of effects on fertility. Therefore, current data does not suggest that the medicine reduces fertility in men or women.


Q: Is it true that Betahistine Accord works by increasing blood flow to the inner ear?

A: Yes, official pharmacological studies indicate that the medicine helps to improve blood circulation in the inner ear's microvasculature. This improved blood flow is understood to contribute to its overall action of stabilizing the balance system.


Q: Does Betahistine Accord interact with cholesterol-lowering medicines?

A: Official in vitro data suggests that the medicine is not expected to cause clinically relevant inhibition of the main Cytochrome P450 (CYP) enzymes. Consequently, interactions with many commonly prescribed drugs, including statins, are generally not anticipated.


Q: What are the most commonly reported side effects, besides stomach issues?

A: Official regulatory documents classify side effects by frequency. Besides common gastrointestinal issues like nausea and indigestion, the other common side effect reported in clinical studies is headache.


Q: How long after stopping Betahistine Accord will it be completely out of my system?

A: The primary substance is cleared relatively quickly. Its main metabolite has a short half-life of about 3.5 hours, indicating that most of the substance is typically eliminated from the body within about a day after the last dose.


Q: Is Betahistine Accord used for vertigo from causes other than Meniere's disease?

A: The official therapeutic indication for the medicine is the treatment of the symptoms associated with Ménière's syndrome. This includes vertigo, tinnitus, and hearing loss, which is the condition for which it is specifically regulated.


Q: Why are there different strengths of Betahistine Accord tablets?

A: The availability of different strengths allows for individualized treatment based on the patient’s need. The total required daily dose, which is typically split across the day, must fall within the officially approved range.

Advertisements

How should Betahistine Accord be stored and disposed of?

Storage Conditions and Requirements

The official storage profile for Betahistine Accord tablets requires specific environmental protection. The medicine must be stored at a temperature below 30°C and should be kept in the original package to ensure protection from moisture. The tablets must also be strictly stored out of the sight and reach of children to prevent accidental ingestion.


Disposal Instructions

Proper disposal is required to protect the environment. Regulatory guidance explicitly states that unused or expired Betahistine Accord must not be disposed of via wastewater or household waste. Patients are instructed to consult their pharmacist for details on returning unused medicine to designated collection points.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Betahistine Accord found in:

A-Z Index: